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1. Introduction 
Currently, tuberculosis (TB) remains a major public health threats of humankind. It has been 
occurred since antiquity and is the second communicable-disease cause of death after the 
human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS). Of 
the mycobacterial diseases, TB is by far the most important because of its most virulence. 
Most of the disease and nearly all of the deaths occurs in the developing countries. Co-
infection with HIV/AIDS and TB represents a public health crisis worldwide. An estimated 
2 billion people worldwide carry latent infection and more than 8 million persons develop 
active TB each year. Approximately, 3 million people per year die from TB (WHO, 2010). 
Various comorbidities, especially the immunocompromised statuses will accelerate the TB 
sickness and deaths. The prevalence of primary drug- (Jiang et al., 2011) and multidrug-
resistant (MDR) (Wells, 2010) pulmonary TB among the immunocompromised populations 
is globally increased. In Thailand, total-estimated TB cases is more than 140,000, now 
ranking 18 of the 22 high-burden countries of the world (WHO, 2010). The clinical features 
of active TB are very highly variable, depend on the immune status of the host and the site 
and extent of disease. New diagnostic, therapeutic, preventive and control strategies for TB 
are heavily investigated throughout the world. How we can rapidly diagnose TB within few 
hours and how we can shorten the treatment regimens to weeks or days. World elimination 
of TB is expected to occur in 2050 when the incidence is 1 patient per 1 million populations 
per year (WHO, 2010).  
2. Epidemiology 
While HIV/AIDS has continued to pose greater threats to the public health system worldwide 
which is a major risk of double increasing within the first year after Mycobacterium tuberculosis 
exposure and 10% per year for developing TB (Barnes et al., 1991, as cited in Silva et al., 2010 & 
Sonnenberg et al., 2001, as cited in Nachega & Maartens, 2009). Now it is clear that non-
communicable comorbidities such as diabetes mellitus, especially type 2 (Goldhaber-Fiebert et 
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al., 2011), malignancies, chronic renal failure, immunosuppressive drug uses as well as 
biological modifiers such as rituximab and infliximab are undoubtedly adding to the multiple 
burdens the people suffer. A previous study in The Philippines demonstrated 37.4% of central 
nervous system TB among patients with systemic lupus erythematosus (SLE) (Vargas et al., 
2009). Multiple immune system abnormalities contribute to high prevalence of TB with SLE 
(Prabu & Agrawal, 2010). Fatal tuberculous myositis at the left thigh was also reported in a 55-
old-male patient with primary Sjӧgren’s syndrome (Huang et al., 2010). TB patients with 
diabetes type 2 have lower antimicrobial peptides gene expression that contribute to enhance 
the TB-reactivation risk (Gonzalez-Curiel et al., 2011). A recent study conducted in India 
showed the ranks of risk factors for developing of TB disease as the following: diabetes 
(30.9%), smoking (16.9%), alcoholism (12.6%), HIV/AIDS (10.6%), malignancies (5.8%), chronic 
hepatic diseases (3.9%), history of TB contact (3.4%), chronic corticosteroid therapy (2.9%), 
chronic renal diseases and malnourishment (1.5%) (Gupta et al., 2011). No evidence was found 
that TB increases the risk of diabetes (Young et al., 2010). There has been a recent evidence of 
increased risk of lung malignancies among pulmonary TB patients and may increase further 
with coexisting chronic obstructive pulmonary disease (COPD) (Yu et al., 2011). A annual TB 
report of the fiscal year 2009 demonstrated that TB patients in northern Thailand who had 
COPD, HIV/AIDS, hypertension and diabetes mellitus ranked 1 to 4 of the specific causes of 
death (10th Zonal Tuberculosis and Chest Disease Centre, Chiang Mai, Thailand and the 10th 
Office of Disease Prevention and Control, Chiang Mai, Thailand, 2009 Tuberculosis annual 
report). A study in Brazil revealed that among the non-HIV-infected immunocompromised 
patients with TB, the only factor statistically related to mortality was the need for mechanical 
ventilation (Silva et al., 2010). In 2009, a total of 300,000 HIV-positive TB patients were enrolled 
on co-trimoxazole preventive therapy, and almost 140,000 were enrolled on antiretroviral 
therapy. In 2006 northern Thailand survey, only 69.6% and 63.1% of the HIV- infected/AIDS 
patients received co-trimoxazole prophylaxis therapy and antiretroviral therapy, respectively 
(10th Zonal Tuberculosis and Chest Disease Centre, Chiang Mai, Thailand and the 10th Office of 
Disease Prevention and Control, Chiang Mai, Thailand, 2006 Tuberculosis annual report). 
Almost 80,000 persons living with HIV were provided with isoniazid preventive therapy. This 
represents less than 1% of estimated number of HIV- infected persons worldwide. The 2015 
targets are HIV testing of 100% of TB patients, enrolment of 100% of HIV-infected TB patients 
on antiretroviral therapy and co-trimoxazole preventive therapy while in 2009 revealed only 
26%, 75% and 37%, respectively (WHO, 2010).  
In northern Thailand, TB is the most common opportunistic infection among HIV- 
infected/AIDS individuals (38.9%) (Cheepsattayakorn et al., 2009). The highest prevalence 
of TB co-infected with HIV/AIDS in northern Thailand appeared in 1999 which was 48.8% 
of the total registered TB cases in the same year compared to 12.2% of the country (10th 
Zonal Tuberculosis and Chest Disease Centre, Chiang Mai, Thailand and the 10th Office of 
Disease Prevention and Control, Chiang Mai, Thailand, 2005 Tuberculosis annual report, 
Figure 1). In 2004 northern Thailand survey revealed that the extrapulmonary site of TB 
among HIV-infected/AIDS cases was accounted for 18.7% of the total TB cases, especially 
TB of the jugular lymph nodes (Cheepsattayakorn & Cheepsattayakorn, 2009). A recent 
study of extrapulmonary TB in a Caucasian population demonstrated that the proportion of 
extrapulmaonry TB has been increased while the overall incidence of TB has been reduced 
(Garcia-Rodriguez et al., 2011). This could be explained by an increase of life expectancy. 
There is no statistically significant difference between the development of pulmonary and 
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extrapulmonary TB among diabetic persons (Young et al,. 2010). A recent study in the 
United States and Mexico revealed high diabetes prevalence among newly-diagnosed TB 
cases which was 39% in Texas and 36% in Mexico, respectively (Restrepo et al., 2011). A 
recent study on TB among end-stage renal disease (ESRD) patients in Taiwan showed that 
the independent risk factors for TB infection in ESRD are male gender, old age, chronic 
obstructive pulmonary disease (COPD), and silicosis (Li et al., 2011). A survey between 
2001-2007 in northern Thailand showed the highest incidence of TB among the populations 
with more than 64 years of age (10th Zonal Tuberculosis and Chest Disease Centre, Chiang 
Mai, Thailand and the 10th Office of Disease Prevention and Control, Chiang Mai, Thailand, 
2007 Tuberculosis annual report, Figure 2).  
 
Fig. 1. TB/HIV/AIDS sentinel surveillance in northern Thailand between 1989-2005. 
 
Fig. 2. Incidence of TB patients by ages in northern Thailand between 2001-2007.  
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3.Tuberculosis investigations in immunocompromised patients 
3.1 Acid-Fast Bacilli (AFB) smear and culture 
The finding of AFB on stained specimens is the only reliable and affordable rapid diagnostic 
method of TB which has lower yield (40%-70%) compared to the mycobacterial culture (75-
90%) (Nachega & Maartens, 2009). 
3.2 Interferon-gamma release assays 
Since 2001, development of interferon-gamma release assays (IGRAs) for the detection of 
TB infection has been initiated in addition to the tuberculin skin test (TST). It detects 
sensitization to Mycobacterium tuberculosis by measuring interferon-gamma release in 
response to Mycobacterium tuberculosis complex antigens (Converse et al., 1997, Rothel et 
al., 1990 & Streeton et al., 1998, as cited in Mazulek et al., 2010 & Walsh et al., 2011). 
QuantiFERON-TB test (QFT) (Cellestis Limited, Carnegie, Victoria, Australia) was the first 
assay approved by the Food and Drug Administration (FDA) in 2001 (FDA, 2010 & 
Mazurek & Villarino, 2003, as cited in Mazulek et al., 2010). The QuantiFERON-TB Gold 
test (GFT-G) (Cellestis Limited, Carnegie, Victoria, Australia) was the second IGRA 
approved by FDA in 2005 (FDA, 2010 & Mazulek et al., 2005, as cited in Mazulek et al., 
2010). The United States Centers for Disease Control and Prevention (CDC) published 
guidelines for using QFT and QFT-G in 2003 and 2005, respectively (Mazurek & Villarino, 
2003, Mazulek et al., 2005, as cited in Mazulek et al., 2010). The CDC recommended that a 
positive interferon-gamma release test should be confirmed with a TST (Mazurek & 
Villarino, 2003, as cited in Hopewell, 2005). A recent study compared the sensitivity of 
QFT- G to enzyme-linked immunospot (ELISPOT) among pulmonary TB including HIV -
negative immunocompromised patients and demonstrated the superiority of ELISPOT 
over QFT-G at the low lymphocyte count conditions, not depending on gender, age, and 
nutritional status (Komiya et al., 2010).  
Many studies have been shown that these new assays are useful for diagnosis of active TB in 
both immunocompromised patients and immunocompetent ones such as HIV/AIDS, 
diabetes mellitus, systemic immunosuppressant administration, malignant diseases and 
chronic renal failure (Ito et al., 2011, Nachega & Maartens, 2009, Tan et al., 2010 & Walsh et 
al., 2011). The sensitivity of the interferon-gamma release assays are not compromised by 
serum glucose levels in TB patients with diabetes (Walsh et al., 2011) including other 
immunocompromised TB patients (Ito et al., 2011). A study demonstrated that, unlike the 
tuberculin skin test, the sensitivity of these assays are less interfered by moderately 
advanced HIV status (Rangaka et al., 2007, as cited in Nachega & Maartens, 2009). The QFT-
G assay has higher detection rate of the latent TB infection than the TST. It may has lower 
sensitivity among the immunocompromised persons but requires shorter turnaround time 
than the TST (Baboolal et al., 2010). A previous study of QuantiFERON-TB Gold In-Tube 
(QFT-GIT) showed 33.4% of indeterminate results among HIV-infected/AIDS patients with 
CD4-T cell count below 200 cells/µL and the TST has higher degree of agreement than QFT-
GIT in patients with immune-mediated inflammatory diseases. This study results indicated 
that the performance of QFT-GIT varied between different types of immunocompromised 
patients (Sauzullo et al., 2010). The CDC do not recommend the blood interferon-gamma 
release assay for pregnant women, individuals with HIV/AIDS, individuals with increased 
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risk of TB, screening children younger than 17 years old, contacts with an infectious case of 
TB, or individuals being evaluated for suspected TB (Mazurek & Villarino, 2003, as cited in 
Hopewell, 2005).  
3.3 Imaging 
Several chest roengenographic pictures plays a critical role in the diagnosis of TB in HIV-
infected/AIDS patients, however, the degree of immunosuppression is a core determinant 
of the roentgenographic appearance. Most notably the presence of bilateral hilar 
lymphadenopathy is highly suggestive of TB, but is not diagnostic (Nachega & Maartens, 
2009, Figure 3). When a CD4+ T-cell count is higher than 200 cells/µL, the pulmonary 
infiltrates are characteristic adult picture with cavitation and upper lobe predominance. But 
when a CD4+ T-cell count is below 200 cells/µL, the pulmonary infiltrates shift toward 
atypical patterns for adults: hilar or mediastinal adenopathy, and mid- ,lower-zone or 
military infiltrates (Nachega & Maartens, 2009, Figure 4). Pleural effusion can occur with 
any CD4+ T-cell count (Havlir & Barnes, 1999, as cited in Nachega & Maartens, 2009, Post et 
al., 1995, Long et al., 1991, as cited in Nachega & Maartens, 2009, Perlman et al., 1997, 
Wendel & Sterling, 2002, as cited in Nachega & Maartens, 2009, Figure 5). There is no 
statistically significant pulmonary shadowing among old patients with TB (Toure′ et al., 
2010). 
 
 
Fig. 3. Chest roentgenogram from the initial presentation of a 34-year-old Thai male with 
HIV-infection/AIDS who attended the tenth Zonal Tuberculosis and Chest Disease Centre, 
Chiang Mai, Thailand showing bilateral hilar adenopathy. The sputum smears for AFB and 
cultures revealed positive results. Diagnosis of pulmonary TB was made. 
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Fig. 4. Chest roentgenogram from initial presentation of a 44-year-old Thai female with 
chronic smoking who attended the tenth Zonal Tuberculosis and Chest Disease Centre, 
Chiang Mai, Thailand showing military infiltrates. Her three consecutive sputum smears for 
AFB and cultures revealed negative results. After completeness of anti-TB chemotherapy 
her chest roentgenogram completely resoluted.  
 
Fig. 5. Chest roentgenogram from initial presentation of another 34-year-old Thai male with 
HIV-infection/AIDS who attended the tenth Zonal Tuberculosis and Chest Disease Centre, 
Chiang Mai, Thailand showing a right massive pleural effusion. His pleural biopsy revealed 
tuberculous pleurisy. 
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A recent study of TB patients with diabetes conducted in India revealed that lower lung 
field involvement was predominant (84%) as compared to upper lung field. Cavitation was 
predominantly confined to the lower lung field (80%) while nodular lesions were found in 
36% and exudative lesions were found in 22% (Patel et al.,2011). A previous report in 2000 
also demonstrated a higher lower-lung field involvement (Perez-Guzman et al., 2000, as 
cited in Patel et al.,2011). Some investigators have demonstrated no major differences of the 
roentgenographic pictures (Bacakoglu et al., 2001, as cited in Patel et al.,2011) while other 
previous studies have reported more common multiple cavities among diabetic patients 
(Sen et al., 2009, as cited in Patel et al.,2011). There are not clear reasons for atypical images 
in TB patients with diabetes. 
Alveolar infiltration which indicates tuberculous pneumonia mostly occurs in the upper 
lung fields is frequently found in HIV-infected/AIDS (20%) and diabetes (15%) patients 
(Moreira et al., 2011). 
Other imaging techniques may be helpful depending on localization of the clinical 
manifestations. Magnetic resonance imaging (MRI) or computed tomography (CT) scans are 
specifically detection of TB of the central nervous system (Figure 6 A & B) while 
ultrasonography can detect intraperitoneal TB such as splenic microabscesses, mesenteric 
lymphadenopathy and hepatic tuberculous granulomas. CT of the chest is superior to chest 
roentgenogram to demonstrate latent TB infiltrate in patient with hepatic transplantation 
(Lyu et al., 2011). 
 
A                                                                   B 
Fig. 6. A: Chest roentgenogram from initial presentation of a 46-year-old Thai male with 
HIV-infection/AIDS who attended the tenth Zonal Tuberculosis and Chest Disease Centre, 
Chiang Mai, Thailand showing bilaterally diffuse reticulo-nodular infiltrates with left 
pleural effusion. His three consecutive sputum smears for AFB and cultures revealed 
positive results. B: Computed tomography of the brain from initial presentation of the same 
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patient in Figure 6 A showing multiple tuberculous granulomas with various sizes 
throughout both parietal lobes.  
3.4 Tuberculin skin test 
The tuberculin skin test is now the standard technique to detect the latent TB infection. The 
sensitivity and specificity of the TST in immunocompromised persons with TB infection are 
very low. A study on latent TB infection during renal replacement therapy in India 
demonstrated that TST was insensitive and nonspecific to detect latent TB infection 
(Bhowmik et al., 2010). The TST in HIV-infected/AIDS patients is more likely to be negative 
due to the declines of the CD4+ T-cell count (Markowitz et al., 1993, as cited in Nachega & 
Maartens, 2009). More than 5 mm. induration on the Mantoux test in HIV-infected/AIDS 
patients is a positive result but this has been challenged by a previous study with sensitivity 
of 64.3% at a cutoff value of 10 mm. and of 71.2%  at  a  cutoff  value  of  5  mm. and after 
adjustment for tuberculosis-specific anergy, the sensitivity was 67.6% and 74.5%, 
respectively (Cobelens et al., 2006, as cited in Nachega & Maartens, 2009). The sensitivity 
and specificity of TST for diagnosis of latent TB infection in patients on renal replacement 
therapy were only 20% and 9%, respectively, showed in a previous study (Agarwal et al., 
2010). The only benefit and effectiveness of the positive-result TST is TB preventive therapy 
(Woldehanna & Volmink, 2004, as cited in Nachega & Maartens, 2009). 
3.5 Tissue aspiration, excision and biopsy 
Aspiration of lymph node with macroscopic tuberculous caseation demonstrates positive 
results 40.8% of cases (Bem et al., 1993, as cited in Nachega & Maartens, 2009, Pithie & 
Chicksen, 1992, as cited in Nachega & Maartens, 2009). Patients with negative-result 
aspiration should be performed needle-core biopsy or excisional biopsy. First needle-core 
biopsy made a definite diagnosis in 85% of cases (Wilson et al., 2005, as cited in Nachega & 
Maartens, 2009). 
3.6 Mycobacterial molecular identification modalities 
3.6.1 Amplicor Polymerase Chain Reaction (PCR) 
A previous study in Kenya showed that the sensitivity and specificity of this technique were 
93% and 94%, respectively and did not affected by the HIV status (Kivihya-Ndugga et al., 
2004, as cited in Cheepsattayakorn & Cheepsattayakorn, 2006). 
3.6.2 IS6110-PCR 
The sensitivity of this technique was 100% in smear-positive, 81.8% in smear- negative, 
66.7% in extrapulmonary, and 42.9% in blood specimens of HIV-infected/AIDS patients as 
demonstrated in a study (Schijman et al., 2004, as cited in Cheepsattayakorn & 
Cheepsattayakorn, 2006). 
3.6.3 Nested PCR 
This technique was studied in urine specimens of the HIV-infected/AIDS participants and 
revealed the sensitivity of 40.5% in smear-positive, 66.7% in smear-negative, and 57.1% in 
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extrapulmonary cases. The overall specificity was 98.2%. This study results were different in 
the non-HIV-infected/AIDS and HIV-infected/AIDS patients (Torrea et al., 2005, as cited in 
Cheepsattayakorn & Cheepsattayakorn, 2006). 
3.6.4 GeneXpert MTB/RIF test 
This test is based on nucleic acid amplification and detection of an Mycobacterium 
tuberculosis-specific region of the rpoB gene, use real-time PCR with molecular beacons. It 
also detects mutation associated with rifampicin resistance. It is fully automated system 
which integrates sputum processing, deoxy-ribonucleic acid extraction, and amplification to 
diagnose TB. Its results are available within 90 minutes. It is minimized biosafety and 
contamination because of its closed system (Lockman, 2011). A clinical study conducted in 
Azerbaijan, India, Peru and South Africa showed the sensitivity of this test for only one 
sputum specimen examination was 92.2% for all positive-culture, 98.2% for positive AFB 
smear and positive culture, and 72.5% for negative AFB smear and positive culture cases 
with a specificity of 99.2%. When 3 specimens were tested the sensitivity was 97.6%, 99.8%, 
and 90.2% with a specificity of 98.1%, respectively (Boehme et al., 2010, as cited in Lockman, 
2011). This test would increase case finding by 30% (replacing or adding to the conventional 
sputum AFB smear) and MDR case finding by 3-fold (replacing sputum culture and 
conventional drug-susceptibility testing) (Boehme et al., 2011, as cited in Lockman, 2011). 
The WHO stated in 2010 that this test should be used as the initial diagnostic test in persons 
suspected of being HIV/AIDS-associated TB or MDR-TB and it may be used as a follow-on 
test in smear-negative specimens where HIV/AIDS and/or MDR are of lesser concern 
(WHO, 2010, as cited in Lockman, 2011). Thailand will soon start using 4 GeneXpert 
MTB/RIF units in collaboration with the United States CDC.  
4. Diagnosis of pulmonary tuberculosis (Sociedade Brasileira de 
Pneumologia e Tisiologia, 2004 & WHO, 2010) 
The diagnosis of pulmonary TB is based on meeting one or more the following criteria: 3.1 
detection by two positive sputum smear examinations 3.2 detection by one positive sputum 
smear examination and positive sputum culture 3.3 detection by one positive sputum smear 
examination and roentgenographic pictures consistent TB positive sputum culture or 3.4 
clinical manifestations, epidemiological findings and roentgenographic pictures consistent 
TB, together with a favorable response to anti-TB drugs.  
5. Antituberculous chemotherapy 
There have been substantial studies from both prospective and retrospective demonstrated 
that standard 6-month rifampicin and isoniazid-contained regimens supplemented by 
pyrazinamide and ethambutol are effective for cure in treating HIV-seropositive patients 
with TB (Hopewell & Chaisson, 2000). The WHO recommends standard regimen 
(2HRZE/4HR, H=isoniazid, R=rifampicin, Z=pyrazinamide, E=ethambutol) for new TB 
patients with seropositive-HIV and all TB patients living in HIV-prevalent settings should 
receive daily antituberculous therapy at least during the intensive phase (Khan et al., 2010, 
as cited in WHO, 2010). Co-trimoxazole preventive therapy should be started as soon as 
possible and prescribed throughout antituberculous therapy (International Standards for 
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Tuberculosis Care (ISTC), 2009, as cited in WHO, 2010) which substantially reduces 
mortality among these patients (Harries et al., 2009, as cited in WHO, 2010 & WHO, 2006). 
The standard 6-month regimen is currently recommended for treating TB of any site, 
excepts of the central nervous system, which is recommended 2HRZE/7HR or 
2HRZE/10HR (Nachega & Maartens, 2009). Recurrent rates of pulmonary TB among 
patients with and without HIV/AIDS have varied among various studies, mostly of 5% or 
less (Kassim et al., 1995, as cited in Nachega & Maartens, 2009, Chaisson et al., 1996, as cited 
in Nachega & Maartens, 2009, el-Sadr et al.,1998, as cited in Nachega & Maartens, 2009, 
Connolly et al.,1999, as cited in Nachega & Maartens, 2009 & Sterling et al., 1999, as cited in 
Nachega & Maartens, 2009). The recurrent rates of TB among HIV-infected/AIDS patients 
were associated with the duration of rifampicin-based regimens which rifampicin durations 
of 2-3, 5-6, and more than 7 months were associated with rates of 4, 2, and 1.4 cases per 100 
person-years, respectively (Korenromp et al., 2003, as cited in Nachega & Maartens, 2009). 
WHO and the International Union Against Tuberculosis and Lung Disease (IUATLD) 
recommends a standardized 6-month rifampicin-based regimen with directly observed 
treatment for highly TB/HIV-endemic, low- income countries for at least the first 2 months 
for all positive-sputum smear cases (Korenromp et al., 2003, as cited in Nachega & 
Maartens, 2009). The IUATLD recommends an 8-month regimen (2HRZE/6HE) for 
negative-smear HIV-infected/AIDS cases but this regimen is related to high relapse rates 
(Korenromp et al., 2003, as cited in Nachega & Maartens, 2009). A study in Zaire among 
HIV-infected/AIDS-related TB patients demonstrated that additional 3 months in the 
continuation phase (2HRZE/7HR) of the standardized 6- month short-course regimen 
(2HRZE/4HR) resulted in 1% versus 8% of relapse rates, respectively but the survival rates 
were no different in patients given extended regimen (Perriens et al., 1995, as cited in 
Hopewell & Chaisson, 2000). Other studies revealed relapse rates of TB with various 
treatment regimens among HIV-infected/AIDS patients between 2%-7% (Kassim et al., 1995, 
as cited in Hopewell & Chaisson, 2000, Chaisson et al., 1996, as cited in Hopewell & 
Chaisson, 2000, el-Sadr et al., 1998, as cited in Hopewell & Chaisson, 2000). The United 
States CDC , the American Thoracic Society (ATS) and the Infectious Disease Society of 
America (IDSA) recommend the extension of the continuation phase from 6 to 9 months of 
the standardized 6-month rifampicin-based regimen for patients with positive cultures and 
cavitary TB, regardless of the HIV status (Chaisson & Nachega, 2010). Acquired- rifampicin 
resistance has been occurred among HIV-infected with advanced immune suppression 
treated with twice weekly rifampicin-based or rifabutin-based regimens (Chaisson & 
Nachega, 2010). The continuation phase of isoniazid plus rifapentine once weekly is 
contraindicated in HIV-infected/AIDS patients because of acquired resistance to rifamycins 
and unacceptably high rate of relapse (Chaisson & Nachega, 2010). Patients with CD4-T cell 
count < 100 cells/µL should receive daily or three-times weekly regimens (Chaisson & 
Nachega, 2010). WHO recommends the same regimens for extrapulmonary and pulmonary 
TB excepts longer treatment for TB of bone or joint and TB of meninges (WHO, 2010). Progress 
against TB is being made on several fronts. Several new drugs are being studied for TB 
therapy, including nitroimidazopyrans (e.g., PA-824), quinolone (moxifloxacin & gatifloxacin), 
oxazolidinones (e.g., PNU-100480, linezolid), macrolides (e.g., clarithromycin, azithromycin), 
ring-substituted imidazoles, and diamines (e.g., SQ109). Finally, new TB vaccines is being 
directed toward developing and should be ready for human testing within a few years. 
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6. Empirical antituberculous therapy 
Empirical therapy will often initiated pending culture results in areas where mycobacterial 
culture is available, especially in areas of high proportion of sputum smear-negative cases 
and relatively rapid disease progression of HIV-related TB. Three consecutive-negative 
smear results, a compatible chest roentgenogram, and no response to a 2-week trial of 
antibiotics for pneumonitis is the common case definition for negative-smear pulmonary TB 
used in resource-poor settings (WHO, 2010, Figure 7). This case definition has been 
modified by WHO to include consideration of acutely-ill patients (especially with 
Pneumocystis pneumonia). If there has been a clinical response with negative-culture 
results, the empirical therapy should be continued. A previous study of case definitions in 
South Africa demonstrated high positive predictive value for a modified case definition of 
negative-smear pulmonary TB and case definitions of extrapulmonary TB and found that 
improvement of symptoms, Karnosky performance score, and serum C-reactive protein 
level were very sensitive to evaluation of the empirical therapy, excepted improvement of 
body weight and hemoglobin level (Wilson et al., 2006, as cited in Nachega & Maartens, 
2009). The specificity of case definitions cannot be 100% so patients who have no response to 
empirical therapy within 2-8 weeks need to be investigated for alternative diagnoses 
discontinuation of their empirical therapy (Nachega & Maartens, 2009). In developing 
countries, the national TB control programs and the international agencies discourage the 
clinical trials of antituberculous therapy.  
 
Fig. 7. TB case management (WHO, 2010) 
7. Antiretroviral therapy 
TB patients with advanced HIV disease/AIDS indicates antiretroviral therapy (ART) which 
improves survival (Harries et al., 2009, as cited in WHO, 2010), reduces TB disease rates by 
60% at a population level, by up to 90% at personal level and reduces TB recurrence rates by 
50% (Lawn & Churchyard, 2009, as cited in WHO, 2010 & Golub et al., 2008, as cited in 
WHO, 2010). Patients co-administered ART and antituberculous therapy may increase risk 
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of adverse drug reactions, especially hepatitis (McIlleron et al., 2007, as cited in Nachega & 
Maartens, 2009). Around 25%-40% of these patients develop the so-called immune 
reconstitute inflammatory syndrome (IRIS) which paradoxically deteriorate TB disease 
(Lawn et al., 2005, as cited in Nachega & Maartens, 2009). Factors related to an increased risk 
of TB-IRIS include rapidly decreasing viral loads, lower CD4+ T-cell count and more shorter 
intervals between starting of antituberculous therapy and ART (Lawn et al., 2005, as cited in 
Nachega & Maartens, 2009). These worsening clinical manifestations should be excluded 
notably poor compliance to antituberculous therapy, systemic drug hypersensitivity 
reactions, MDR-TB, and new opportunistic infections. The most common manifestation of 
TB-IRIS is enlarging lymphadenopathy with caseous necrosis. The optimal timing of starting 
ART in relation to starting antituberculous therapy is unclear but TB treatment should 
always be initiated first, and waits at least until the patient is tolerating the antituberculous 
therapy before initiating ART as soon as possible and within the first 8 weeks of initiating 
antituberculous therapy (Nachega & Maartens, 2009 & WHO, 2010). All active-TB patients 
living with HIV should be initiated ART irrespective of CD4+ T-cell count (WHO, 2009, as 
cited in WHO, 2010). In 2010 Thailand’s guidelines, starting ART when CD4 T-cell count is 
below 350 cells/µL. Patients who are already receiving an ART regimen, ART should be 
continued (Nachega & Maartens, 2009). WHO recommends the first-line ART regimens 
contain two nucleoside reverse transcriptase inhibitors (NRTIs-zidovudine (AZT) or 
tenofovir disproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC)) plus one 
non-nucleoside reverse transcriptase inhibitors (NNRTI-efavirenz (EFV) or nevirapine 
(NVP)) (WHO, 2010). In Thailand, the available regimens are stavudine plus lamivudine 
plus efavifenz or stavudine plus lamivudine plus nevirapine or stavudine plus lamivudine 
plus indinavir or ritonavir (Cheepsattayakorn & Cheepsattayakorn, 2009). 
8. Adjunctive glucocorticoids in TB patients with HIV-infection/AIDS 
There is lacking of evidence base for adjunctive glucocorticoids among these patients. There 
is likely to be a mortality benefit when used in HIV-infected/AIDS patients with 
tuberculous meningitis and pericarditis, but more larger studies are needed (Nachega & 
Maartens, 2009). 
9. Adjuvant immunotherapy 
A previous study demonstrated that immunization with killed Mycobacterium vaccae had 
ability to modify immune response to TB, but failed to showed clinical benefit in HIV- 
infected/AIDS patients (Mwinga et al., 2002, as cited in Nachega & Maartens, 2009). 
10. Monitoring during antituberculous therapy 
Sputum-smear examinations at the completion of the intensive phase of treatment course is 
a conditional, rather than a strong WHO recommendation (WHO, 2010). The evidence of a 
positive smear at this stage has a very poor ability to predict relapse or pretreatment 
isoniazid resistance (WHO, 2010). A positive-sputum smear at the end of the intensive phase 
among new patients should trigger sputum-smear examinations at the end of the third 
month and if it is positive, sputum culture and antituberculous-drug susceptibility testing 
should be done (WHO, 2010). There is no longer recommends to extend the intensive phase 
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for patients have a positive-sputum smear at the end of the second month of treatment 
course (WHO, 2010). 
11. Antituberculous therapy in non-HIV-infected immunocompromised 
patients 
Regimens used in these patients are the same as used in HIV-infected/AIDS patients except 
regimens used in military TB, TB of bone or joint, and meninges which are more longer than 
6 months, usually at least 8 months (WHO, 2010).  
12. Treatment of latent TB infection 
The IUATLD conducted a study in Eastern Europe and revealed that 3 months of isoniazid 
therapy reduced the TB incidence by 20%, 66% for 6 months, and 75% for 12 months 
(Chaisson & Nachega, 2010). This study also resulted in 92% reduction in TB risk for 
patients completing 12 months of isoniazid compared to 69% decrease for patients 
completing the standard-6 month regimen. A recent study in Alaskan populations revealed 
that the optimal duration of isoniazid therapy was 9 months therefore, the new ATS/CDC 
recommendation is 9 months of isoniazid as the preferred regimen, and the alternative 
regimen is 6 months (Chaisson & Nachega, 2010). A previous study in northern Thailand 
showed that 78% of HIV-infected/AIDS patients did not have TB disease at the end of 24 
months after completion of 9 months of isoniazid therapy (Cheepsattayakorn, 1998, as cited 
in Cheepsattayakorn & Cheepsattayakorn, 2009). 
13. Bacille Calmette-Gue′rin (BCG) vaccination 
The protective benefit of BCG for active TB disease and death is about 50% (Chaisson & 
Nachega, 2010). It decrease hematogenous dissemination of primary TB infection and so 
reduces the incidence of military TB and childhood tuberculous meningitis (Chaisson & 
Nachega, 2010). BCG should not be given to immunocompromised individuals, including 
those with HIV-infection/AIDS, or to pregnant women (Hopewell, 2005).  
14. Further research areas 
It demonstrates that the WHO’s DOTS strategy for case finding and effectively treating 
cases is not sufficient to eliminate TB, particularly in countries with HIV epidemics. Neither 
combination ART nor treatment of latent TB infection has a significant impact on 
community TB incidence. The most effective measures are reduced HIV incidence and 
improved TB case finding and treatment success rates. A better understanding of natural 
immunity to TB and its pathogenesis may contribute to the development of a new more 
effective vaccine. The genome sequencing of Mycobacterium tuberculosis promises to produce 
a new generation of TB control research.  
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